24 results
8-K
EX-10.1
NBSE
NeuBase Therapeutics Inc
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
regarding the Company or its Subsidiaries or their financial results or prospects.
(jj) Cybersecurity. (i)(x) There has been no security breach
8-K
EX-10.2
NBSE
NeuBase Therapeutics Inc
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
or prospects.
(nn) Cybersecurity. (i)(x) There has been no security breach or other compromise of or relating to any of the Company’s or any
424B5
NBSE
NeuBase Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
8:42am
significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity … against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters, or from
424B5
po271
29 Dec 22
Prospectus supplement for primary offering
5:03pm
424B5
1x7 q5qvp8
27 Aug 21
Prospectus supplement for primary offering
5:21pm
8-K
EX-1.1
0cwf9x
27 Aug 21
Entry into a Material Definitive Agreement
12:00am
424B5
x2ahulfm6ouce
23 Apr 21
Prospectus supplement for primary offering
4:05pm
424B5
j6vpa62wgs3yy4nh8
21 Apr 21
Prospectus supplement for primary offering
4:03pm
424B3
fhauf9cpu6fqvhchvxi0
6 Jun 19
Prospectus supplement
5:15pm